文献速递肝胆胰外科围术期管理与 ERAS

机器人与开腹肝切除治疗原发性肝肿瘤的多中心回顾性对比研究

Comparison of robotic and open liver resections for primary liver tumors: a multicenter retrospective analysis of perioperative outcomes, morbidity and mortality.
PubMed 文献 · Surg Endosc · 2026-01-22

该多中心回顾性研究纳入100例肝细胞癌或肝内胆管癌患者,比较机器人肝切除(RLR,65例)与开腹肝切除(OLR,35例)的围手术期结局。RLR组住院时间更短、出血量更少,并发症率、90天死亡率与R0切除率与OLR组相当,但OLR组更多用于复杂切除。

要点

  • RLR与更短住院时间和更少出血量相关。
  • 两组严重并发症、90天死亡率及R0切除率无显著差异。
  • OLR更多应用于复杂切除及血管切除、胆肠吻合病例。

核心结论

  • 在选择的HCC或iCC患者中,RLR与更短住院时间、更少出血量相关,并发症率与OLR相当。
  • OLR更多用于更复杂的切除,并倾向于血管切除和胆肠吻合。

研究设计与样本

  • 多中心回顾性研究,纳入Ulm大学医院(2020年11月至2023年9月)和纽伦堡医院(2023年12月至2025年6月)因HCC或iCC行肝切除的患者。
  • 共100例患者,RLR组65例,OLR组35例;比较人口学、手术数据(包括IWATE评分)和术后结局,使用Fisher精确检验和Mann-Whitney U检验(p<0.05)。

主要发现

  • RLR组中位年龄68.0岁(IQR 63.0-74.0),OLR组70.05岁(IQR 63.5-78.3)。
  • RLR组住院时间显著更短(5天[IQR 4-7] vs 11天[IQR 7-20.5],p<0.001)。
  • RLR组出血量显著更少(300 ml [IQR 100-625] vs 750 ml [IQR 400-1450],p=0.001)。
  • RLR组手术时间有更低趋势(173 min [IQR 135-237] vs 219 min [IQR 177-287],p=0.072)。
  • RLR组IWATE评分更低(6.0 [IQR 5.0-9.0] vs 8.5 [IQR 7.0-10.0],p=0.004)。

关键数值与推荐

  • 胆漏发生率RLR组4.6% vs OLR组17.1%(p=0.062)。
  • 再干预率RLR组7.7% vs OLR组14.2%(p=0.313)。
  • 严重并发症(Clavien-Dindo ≥ IIIa)RLR组30.8% vs OLR组48.6%(p=0.087)。
  • 术后肝衰竭RLR组15.4% vs OLR组28.6%(p=0.126);术后出血RLR组0% vs OLR组5.7%(p=0.120)。
  • 90天死亡率RLR组4.6% vs OLR组5.7%(p=1.0);R0切除率RLR组76.6% vs OLR组82.9%(p=0.28)。

临床怎么用

  • 对于选择的HCC或iCC患者,RLR可考虑作为OLR的微创替代方案。
  • 复杂切除、需血管切除或胆肠吻合的病例仍倾向于选择OLR。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 样本量较小(共100例),部分比较可能统计效能不足。
  • RLR组IWATE评分更低,提示两组切除复杂度存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robotic liver resection (RLR) has emerged as a minimally invasive alternative to open liver resection (OLR) for selected primary liver tumors, but its application for major hepatectomies remains limited. METHODS: This retrospective study included patients who underwent hepatectomy for hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCC) at Ulm University Hospital (Nov 2020-Sep 2023) and Klinikum Nuremberg (Dec 2023-Jun 2025). Patients underwent RLR (n = 65) or OLR (n = 35). Demographics, operative data (including IWATE score), and postoperative outcomes-length of stay (LOS), blood loss, complications (Clavien-Dindo), and 90-day mortality-were compared using Fisher's exact and Mann-Whitney U tests (p < 0.05). RESULTS: A total of 100 patients were analyzed. Median age was 68.0 years (IQR 63.0-74.0) in RLR vs. 70.05 years (IQR 63.5-78.3) in OLR. LOS was significantly shorter after RLR (5 days [IQR 4-7] vs. 11 days [IQR 7-20.5], p < 0.001). Operative time tended to be lower with RLR (173 min [IQR 135-237] vs. 219 min [IQR 177-287], p = 0.072), and blood loss was significantly reduced (300 ml [IQR 100-625] vs. 750 ml [IQR 400-1450], p = 0.001). Bile leakage occurred in 4.6% (RLR) vs. 17.1% (OLR) (p = 0.062); re-interventions in 7.7% vs. 14.2% (p = 0.313). Severe complications (Clavien-Dindo ≥ IIIa) were less frequent after RLR (30.8% vs. 48.6%, p = 0.087). Post-hepatectomy liver failure occurred in 15.4% vs. 28.6% (p = 0.126); post-hepatectomy hemorrhage in 0% vs. 5.7% (p = 0.120). Ninety-day mortality was 4.6% (RLR) vs. 5.7% (OLR) (p = 1.0). IWATE scores were lower in RLR (6.0 [IQR 5.0-9.0]) vs. OLR (8.5 [IQR 7.0-10.0], p = 0.004). R0 resection was achieved in 76.6% in RLR vs. 82.9% in OLR (p = 0.28). CONCLUSION: In selected HCC or iCC patients, RLR was associated with shorter hospitalization, reduced blood loss, and with comparable complication rates in the full cohort and subgroup analysis. Overall OLR was applied to more complex resections and favored in vascular resection and biliodigestive anastomoses. These findings support RLR integration and highlight the need for prospective studies in complex cases.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Steinkraus KC, Schlag F, Mihaljevic AL, et al. Comparison of robotic and open liver resections for primary liver tumors: a multicenter retrospective analysis of perioperative outcomes, morbidity and mortality. Surg Endosc. 2026. PMID: 41571989. doi:10.1007/s00464-026-12566-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。